← Back

Context Therapeutics Inc

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of solid tumors. Its product candidate, CTIM-76, is a Claudin 6 (CLDN6) x CD3 bispecific antibody designed to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Incorporated in 2015, it is headquartered in Philadelphia, Pennsylvania.

Price · split & dividend adjusted
News & notes moving CNTX
United StatesAustralia
Biotech & Genomic Medicine▼

Context Therapeutics Q2 Net Loss Widens 65% to $14.56 Million, Stock Drops 23% in Overnight Trading

Context Therapeutics reported a second-quarter net loss of $14.56 million, a 65% increase from $8.83 million a year earlier, as it advances its clinical pipeline. Diluted loss per share rose to $0.15 from $0.09. The company held $43 million in cash and equivalents as of June 30, 2026, with a runway expected to fund operations through the fourth quarter of 2027. Its lead candidate CTIM-76 received FDA Fast Track Designation in April 2026 for platinum-resistant ovarian cancer, with a Phase 1b dose expansion trial set to begin in the first quarter of 2027. A second asset, CT-202, gained Australian regulatory clearance to start a first-in-human Phase 1 trial, with initial topline data anticipated in the second half of 2027. Context also discontinued development of CT-95 to focus resources on its two lead programs. The stock closed Wednesday at $0.69, up 11.45%, but fell 23.06% to $0.53 in overnight trading.
CNTX ▼
Biotech & Genomic Medicine ▼
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics ▼Capital
CNTX · Capital · Negative Q2 net loss widened 65% and stock dropped 23% in overnight trading
Read original ↗
RTTNews·62dRead more →
CNTX▲

Context Therapeutics Added to Russell 2000 and Russell 3000 Indices

Context Therapeutics has been added to the Russell 2000 and Russell 3000 indices effective June 26, 2026. The Russell 3000 index comprises the 3000 largest publicly traded companies in the U.S., representing about 98% of the investable market, while the Russell 2000 is a subset that serves as a leading benchmark for U.S. small-cap equities. Context is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies targeting solid tumors, including CTIM-76, CT-95, and CT-202. Shares closed Monday at $0.64, down 2.46%, and were trading at $0.66 in the pre-market, up 3.43%.
CNTX ▲
CNTX · Capital · Positive Inclusion in Russell indices typically triggers passive fund buying and increased visibility.
Read original ↗
RTTNews·92dRead more →
Biotech & Genomic Medicine▲

Maxim Says Context Therapeutics Share Pullback Is an Overreaction

Maxim analyst Jason McCarthy lowered the price target on Context Therapeutics to $4 from $8 while maintaining a Buy rating, calling the sharp negative stock reaction to interim Phase 1a data for CTIM-76 an overreaction. The study remains exploratory and focused on learning about the drug's pharmacokinetic profile, dosing, safety, and initial efficacy. Jones Research also described the selloff as a buying opportunity, keeping a Buy rating and $7 price target, and pointing to a 29% overall response rate in platinum-resistant ovarian cancer patients who had a median of seven prior therapies. H.C. Wainwright analyst Emily Bodnar noted competitive activity versus peers despite a challenging patient population, reiterating a Buy rating and $5 price target. Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors.
CNTX ▲
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics Technology
CNTX · Capital · Positive Multiple analysts maintain Buy ratings and call the post-data selloff an overreaction, with price targets of $4-$7.
Read original ↗
Insider Monkey·93dRead more →
© 2026 MarketIVAsset